Virus infection inhibitor, resin composition, and virus infection inhibiting product

Abstract

Provided is a virus infection inhibitor capable of substantially preventing the occurrence of yellowing even when placed in a high-temperature environment. A virus infection inhibitor according to the present invention comprises: a carrier having a specific surface area of 1-1000 m2 / g; and a viral infection-inhibiting compound supported on the support and containing at least one infection-inhibiting functional group selected from the group consisting of a carboxyl group, a sulfo group, a primary amino group, a secondary amino group, and a tertiary amino group, or a salt thereof, or a viral infection-inhibiting compound supported on the support and containing a guanidine structure.

Description

Technical Field

[0001] The present invention relates to a virus infection inhibitor, a resin composition and a virus infection inhibitory product. Background Art

[0002] In recent years, in addition to the epidemic of seasonal influenza viruses, the new coronavirus (COVID-19) is spreading worldwide.

[0003] In addition, the highly pathogenic avian influenza virus has mutated and has been confirmed to be transmitted from person to person. In addition, there are concerns about the SARS virus with an extremely high mortality rate, and the sense of insecurity about viruses is increasing.

[0004] In view of these problems, Patent Document 1 proposes an antiviral surface treatment agent, which is composed of a coating containing an antiviral agent, wherein the antiviral agent is calcium carbonate supported by a sulfonic acid surfactant, and the coating is an ultraviolet curing coating or an electron beam curing coating.

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: Japanese Patent Application Publication No. 2016-128395 Summary of the invention

[0008] Technical problem solved by the invention

[0009] However, the antiviral surface treatment agent has a problem of yellowing when left in a high temperature environment. In addition, when the antiviral surface treatment agent is contained in a coating, it aggregates, so there is a problem of low coating properties.

[0010] The present invention provides a virus infection inhibitor that can substantially prevent yellowing (hereinafter referred to as "yellowing resistance") even when left in a high-temperature environment, and a resin composition and a virus infection inhibitor product using the virus infection inhibitor.

[0011] The present invention provides a virus infection inhibitor which, when contained in a coating material, can be uniformly dispersed in the coating material without agglomeration, and can prepare a coating material having excellent coating properties (hereinafter referred to as "coating properties").

[0012] Technical means of solving problems

[0013] The virus infection inhibitor of the present invention comprises:

[0014] Specific surface area is 1~1000m 2 / g of carrier; and

[0015] A virus infection inhibitory compound supported on the carrier and containing at least one infection inhibitory functional group selected from carboxyl, sulfonyl, primary amino, secondary amino and tertiary amino groups or a salt thereof, or a virus infection inhibitory compound supported on the carrier and containing a guanidine structure.

[0016] The resin composition of the present invention comprises a synthetic resin and the viral infection inhibitor.

[0017] The viral infection inhibiting product of the present invention comprises: a base material, and the viral infection inhibiting agent contained in the base material.

[0018] Effects of the Invention

[0019] Since the virus infection inhibitor of the present invention has the above-mentioned structure, it hardly turns yellow even when left in a high-temperature environment, and does not aggregate even when mixed in a coating material, so that a coating material having excellent coating properties can be prepared.

[0020] Since the virus infection inhibitor of the present invention has excellent yellowing resistance, it can impart a virus infection inhibitory effect to a substrate while maintaining the appearance of the substrate, without impairing the appearance of the substrate, such as the color. DETAILED DESCRIPTION

[0021] The virus infection inhibitor of the present invention comprises:

[0022] Specific surface area is 1~1000m 2 / g of carrier; and

[0023] A virus infection inhibitory compound supported on the carrier and containing at least one infection inhibitory functional group selected from carboxyl, sulfonyl, primary amino, secondary amino and tertiary amino groups or a salt thereof, or a virus infection inhibitory compound supported on the carrier and containing a guanidine structure.

[0024] [Viral infection inhibitory compounds]

[0025] The virus infection inhibitor of the present invention contains a virus infection inhibitor compound as an active ingredient. The virus infection inhibitor compound has at least one infection inhibitory functional group selected from carboxyl group (-COOH), carboxyl salt, sulfonyl group (-SO3H), sulfonyl salt, primary amino group, primary amino salt, secondary amino group, secondary amino salt, tertiary amino group and tertiary amino salt, or guanidine structure in the molecule.

[0026] In the virus infection inhibitory compound, the virus infection inhibitory functional group and the guanidine structural part exhibit a virus infection inhibitory effect. The virus infection inhibitory compound has an excellent virus infection inhibitory effect on both enveloped viruses and non-enveloped viruses.

[0027] It should be noted that the virus infection inhibitory effect refers to the effect of eliminating or reducing the infectivity of the virus to the cell, or preventing the virus from proliferating in the cell even if infected. As a method for confirming the presence or absence of such virus infectivity, ISO18184 and JIS L1922 can be cited for fiber products, and ISO21702 can be cited for plastics other than fiber products and products with non-porous surfaces. The Antimicrobial Products Technology Agreement (SIAA) certifies the antiviral processing mark for products that meet the safety of antiviral processing agents and certain antiviral effect standards. The standard for the antiviral effect is that the difference (antiviral activity value) between the common logarithm of the virus infection titer of the blank product (antiviral processing agent without additives) and the common logarithm of the virus infection titer of the processed product (antiviral processing agent additives) is 2.0 or more in the evaluation of ISO21702. The virus infection inhibitor is used as a component of the antiviral processing agent, mixed into the resin, or added to the surface coating agent such as the coating, and evaluated by the above evaluation method.

[0028] In the present invention, for example, when evaluating the virus infection inhibitory effect under the following conditions, the case where the difference in the common logarithmic value of the virus infection titer between the blank and the processed product (antiviral activity value) is 2.0 or more is defined as a virus infection inhibitor. In this case, regardless of the type of virus evaluated, in at least one virus, the difference in the common logarithmic value of the virus infection titer between the blank and the processed product (antiviral activity value) is 2.0 or more is treated as a virus infection inhibitor.

[0029] For example, 50 mg of a virus infection inhibitor is added to 950 mg of a solvent-free ultraviolet curable acrylic resin and uniformly mixed to prepare a coating. The coating is applied to a polyethylene film in such a manner that the thickness of the obtained coating is 18 μm to form a coating layer. The ultraviolet light with a wavelength of 365 nm is used as the irradiation light amount of 500 mJ / cm 2 The coating layer was irradiated with UV light in a manner to cure the ultraviolet curable acrylic resin, thereby forming a coating film with a film thickness of 18 μm as a test coating film.

[0030] The obtained test film was subjected to an antiviral test based on ISO21702. The virus infection titer of the test film was calculated by the plaque method for the virus suspension after the reaction. A blank film was prepared in the same manner as described above except that the virus infection inhibitor was not included, and the virus infection titer (common logarithm) (PFU / cm 2 ). The difference in the common logarithmic values ​​of the virus infection titers (antiviral activity value) was calculated by subtracting the virus infection titer of the test coating from the virus infection titer of the blank coating.

[0031] In addition, the plaque method and hemagglutination titer (HAU) measurement method described in "Medical Virology" (first edition published in April 1990) can be cited.

[0032] The salt of the carboxyl group (-COOH) is not particularly limited, and examples thereof include sodium salt (-COONa), calcium salt [(-CO - )2Ca 2+ ], ammonium salt (-COO - NH4 + ), magnesium salt [(-COO - )2Mg 2+ ], barium salt [(-COO - )2Ba 2+ ] etc., preferably sodium salt.

[0033] The salt of the sulfonic acid group (-SO3H) is not particularly limited, and examples thereof include sodium salt (-SO3Na), calcium salt [(-SO3 - )2Ca 2+ ], ammonium salt (-SO3 - NH4 + ), magnesium salt [(-SO3 - )2Mg 2+ ]、barium salts [(-SO3 - )2Ba 2+ ] etc., preferably sodium salt.

[0034] The virus infection inhibitory compound having a carboxyl group may have one or more carboxyl groups in the molecule, and examples thereof include polymers having a carboxyl group on the side chain of a linear polymer, mellitic acid, aconitic acid, citric acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, fumaric acid, maleic acid, itaconic acid, citraconic acid, mesaconic acid, phthalic acid, isophthalic acid, terephthalic acid, methylenedisalicylic acid, cis-Δ4-tetrahydrophthalic acid, gluconic acid, mucic acid, 3,3'-thiodipropionic acid, 2,2'-thiodiglycolic acid, 3,3'-dithiodipropionic acid, 2,2'-dithiodiglycolic acid, 2,2'-dithiosalicylic acid, 4,4'-dithiodibutyric acid, 3-(dodecylthio)propionic acid, picolinic acid, formic acid , acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, lauric acid, crotonic acid, glycolic acid, lactic acid, malic acid, tartaric acid, quinic acid, salicylic acid, benzoic acid, vanillic acid, gallic acid, mandelic acid, benzilic acid, phlorotactic acid, coumaric acid, caffeic acid, ferulic acid, sinapic acid, 4-aminobenzoic acid, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, carboxymethyl cellulose, carboxymethyl chitosan, carboxymethyl chitin, carboxymethyl dextran, carboxymethyl-β-cyclodextrin, carboxysucrose, pectin, xanthan gum, alginic acid, hyaluronic acid, fulvic acid, humic acid, uronic acid, arabinonic acid, fructonic acid, tagaturonic acid, glucuronic acid, iduronic acid, galacturonic acid, mannuronic acid, guluronic acid, etc.

[0035] Among the polymers having a carboxyl group on the side chain of the linear polymer, the linear polymer is not particularly limited, and for example, a vinyl polymer, a polyester, and a polyurethane are preferred, and a vinyl polymer is more preferred.

[0036] As the polymer with carboxyl on the side chain of linear polymer, for example, can enumerate the polymer etc. containing the carboxyl-containing monomer as monomeric unit.The polymer containing the carboxyl-containing monomer as monomeric unit can be the homopolymer of carboxyl-containing monomer, and can also be the copolymer of carboxyl-containing monomer and the monomer copolymerizable therewith.In the polymer containing the carboxyl-containing monomer as monomeric unit, the content of the carboxyl-containing monomer is preferably more than 50 mol %, more preferably more than 75 mol %, more preferably more than 90 mol %, more preferably more than 95 mol %, more preferably more than 99 mol %, more preferably 100 mol %.

[0037] The carboxyl-containing monomer is not particularly limited, and examples thereof include acrylic acid, methacrylic acid, β-carboxyethyl (meth)acrylate, 5-carboxypentyl (meth)acrylate, mono(meth)acryloyloxyethyl succinate, ω-carboxypolycaprolactone mono(meth)acrylate, crotonic acid, maleic acid, fumaric acid, itaconic acid, citraconic acid, carboxybetaine-type monomers, etc., preferably acrylic acid and methacrylic acid. It should be noted that the carboxyl-containing monomer can be used alone or in combination of two or more. (Meth)acrylate means acrylate or methacrylate. (Meth)acryloyl means acryloyl or methacryloyl.

[0038] The virus infection inhibitory compound containing a salt of a carboxyl group may be a salt having one or more carboxyl groups in the molecule. Examples thereof include polymers having a salt of a carboxyl group on the side chain of a linear polymer, salts of mellitic acid, salts of aconitic acid, salts of citric acid, salts of oxalic acid, salts of malonic acid, salts of succinic acid, salts of glutaric acid, salts of adipic acid, salts of pimelic acid, salts of suberic acid, salts of fumaric acid, salts of maleic acid, salts of itaconic acid, salts of citraconic acid, salts of mesaconic acid, salts of phthalic acid, salts of isophthalic acid, salts of isophthalic acid, phthalic acid salts, methylenedisalicylic acid salts, cis-Δ4-tetrahydrophthalic acid salts, gluconic acid salts, mucic acid salts, 3,3'-thiodipropionic acid salts, 2,2'-thiodiglycolic acid salts, 3,3'-dithiodipropionic acid salts, 2,2'-dithiodiglycolic acid salts, 2,2'-dithiosalicylic acid salts, 4,4'-dithiodibutyric acid salts, 3-(dodecylthio)propionic acid salts, picolinic acid salts, formic acid salts, acetic acid salts, propionic acid salts, butyric acid salts, valeric acid salts salts of caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, lauric acid, crotonic acid, glycolic acid, lactic acid, malic acid, tartaric acid, quinic acid, salicylic acid, benzoic acid, vanillic acid, gallic acid, mandelic acid, benzilic acid, phlorotactic acid, coumaric acid, caffeic acid, ferulic acid, sinapic acid, 4-aminobenzoic acid, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriamine Salts of triaminepentaacetic acid, salts of carboxymethyl cellulose, salts of carboxymethyl chitosan, salts of carboxymethyl chitin, salts of carboxymethyl dextran, salts of carboxymethyl-β-cyclodextrin, salts of carboxysucrose, salts of pectin, salts of xanthan gum, salts of alginic acid, salts of hyaluronic acid, salts of fulvic acid, salts of humic acid, salts of uronic acid, salts of arabinonic acid, salts of fructose uronic acid, salts of tagatose uronic acid, salts of glucuronic acid, salts of iduronic acid, salts of galacturonic acid, salts of mannuronic acid, salts of guluronic acid, and the like.

[0039] Among the polymers having a salt of a carboxyl group on the side chain of the linear polymer, the linear polymer is not particularly limited, and for example, a vinyl polymer, a polyester, and a polyurethane are preferred, and a vinyl polymer is more preferred.

[0040] As the polymer having a salt of a carboxyl group on the side chain of the linear polymer, for example, a polymer containing a monomer of a salt of a carboxyl group as a monomer unit can be mentioned. The polymer containing a monomer of a salt of a carboxyl group as a monomer unit can be a homopolymer of the monomer of the salt of a carboxyl group, or a copolymer of the monomer of the salt of a carboxyl group and a monomer copolymerizable therewith. In the polymer containing a monomer of a salt of a carboxyl group as a monomer unit, the content of the monomer of the salt of a carboxyl group is preferably 50 mol% or more, more preferably 75 mol% or more, more preferably 90 mol% or more, more preferably 95 mol% or more, more preferably 99 mol% or more, and more preferably 100 mol%.

[0041] The monomer of the carboxyl salt is the salt of the carboxyl group of the carboxyl monomer. As the salt of the monomer of the carboxyl salt, sodium salt, calcium salt, ammonium salt, magnesium salt, barium salt etc. can be mentioned, preferably sodium salt. It should be noted that the carboxyl monomer is the same as above, so the description is omitted.

[0042] As the virus infection inhibitory compound containing a sulfonic group, it is sufficient to have one or more sulfonic groups in the molecule, and examples thereof include polymers having a sulfonic group on the side chain of a linear polymer, polystyrene sulfonic acid, formamidine sulfinic acid, 3-aminobenzenesulfonic acid, hydroxybenzenesulfonic acid, m-xylene-4-sulfonic acid, 5-sulfosalicylic acid, p-aminobenzenesulfonic acid, 2-amino-3,5-dimethylbenzenesulfonic acid, 1,3-phenylenediamine-4-sulfonic acid, sulfonated (styrene-divinylbenzene copolymer), carrageenan, sulfonated polyethersulfone, lignin sulfonic acid, taurine, and the like.

[0043] Among the polymers having a sulfonic group on the side chain of the linear polymer, the linear polymer is not particularly limited, and for example, a vinyl polymer, a polyester, and a polyurethane are preferred, and a vinyl polymer is more preferred.

[0044] Examples of the polymer having a sulfonic group on the side chain of the linear polymer include a polymer containing a sulfonic group-containing monomer as a monomer unit. In the polymer containing a sulfonic group-containing monomer as a monomer unit, the content of the sulfonic group-containing monomer is preferably 50 mol% or more, more preferably 75 mol% or more, more preferably 90 mol% or more, more preferably 95 mol% or more, more preferably 99 mol% or more, and more preferably 100 mol%.

[0045] Examples of the polymer containing a sulfonic group-containing monomer containing a sulfonic group as a monomer unit include a polymer containing a styrene sulfonic acid unit, a homopolymer of styrene sulfonic acid, a styrene-styrene sulfonic acid copolymer, a compound obtained by sulfonating the benzene ring of polystyrene, and a compound obtained by sulfonating the benzene ring of a polymer containing a styrene component.

[0046] The sulfone group-containing monomer is not particularly limited, and examples thereof include p-styrenesulfonic acid, m-styrenesulfonic acid, and o-styrenesulfonic acid.

[0047] As the virus infection inhibiting compound containing a salt of a sulfonic group, any salt having one or more sulfonic groups in the molecule may be mentioned, and examples thereof include linear alkylbenzene sulfonates, α-olefin sulfonates, alkyldiphenyl ether sulfonates, polyoxyalkylene alkyl ether sulfate ester salts, lauryl sulfates, polymers having a salt of a sulfonic group on the side chain of a linear polymer, salts of polystyrene sulfonic acid, salts of formamidine sulfinic acid, salts of 3-aminobenzenesulfonic acid, salts of hydroxybenzenesulfonic acid, salts of m-xylene-4-sulfonic acid, salts of 5-sulfosalicylic acid, salts of p-aminobenzenesulfonic acid, salts of 2-amino-3,5-dimethylbenzenesulfonic acid, salts of 1,3-phenylenediamine-4-sulfonic acid, salts of sulfonated (styrene-divinylbenzene copolymer), salts of carrageenan, salts of sulfonated polyethersulfone, salts of lignin sulfonic acid, and the like.

[0048] Examples of the linear alkylbenzene sulfonate include sodium dodecylbenzene sulfonate, calcium dodecylbenzene sulfonate, ammonium dodecylbenzene sulfonate, magnesium dodecylbenzene sulfonate, barium dodecylbenzene sulfonate, sodium tridecylbenzene sulfonate, ammonium tridecylbenzene sulfonate, sodium tetradecylbenzene sulfonate, and ammonium tetradecylbenzene sulfonate. Sodium dodecylbenzene sulfonate is preferred.

[0049] Examples of the α-olefin sulfonate include sodium C12-C18 olefin sulfonate, calcium C12-C18 olefin sulfonate, ammonium C12-C18 olefin sulfonate, magnesium C12-C18 olefin sulfonate, barium C12-C18 olefin sulfonate, and the like. Sodium C14 tetradecene sulfonate is preferred.

[0050] Examples of alkyl diphenyl ether sulfonates include sodium salts, calcium salts, ammonium salts, magnesium salts, and barium salts of alkyl diphenyl ether sulfonic acids having an alkyl group of C6 to C18. The alkyl group refers to a monovalent atomic group remaining after removing one hydrogen atom from an aliphatic saturated hydrocarbon.

[0051] In the polymer having a salt of a sulfonic group on a side chain of a linear polymer, the linear polymer is not particularly limited, and for example, a vinyl polymer, a polyester, and a polyurethane are preferred, and a vinyl polymer is more preferred.

[0052] The polymer having a salt of a sulfonic group on the side chain of the linear polymer is not particularly limited, and examples thereof include a polymer containing a sulfonic group-containing salt monomer as a monomer unit. In the polymer containing a sulfonic group-containing salt monomer as a monomer unit, the content of the sulfonic group-containing salt monomer is preferably 50 mol% or more, more preferably 75 mol% or more, more preferably 90 mol% or more, more preferably 95 mol% or more, more preferably 99 mol% or more, and more preferably 100 mol%.

[0053] Examples of the polymer containing a sulfonate-containing salt monomer as a monomer unit include a polymer containing a styrene sulfonate unit, a homopolymer of styrene sulfonate, a styrene-styrene sulfonate copolymer, a sulfonate of a compound obtained by sulfonating the benzene ring of polystyrene, and a sulfonate of a compound obtained by sulfonating the benzene ring of a polymer containing a styrene component.

[0054] The monomer of the salt containing a sulfonic group is not particularly limited, and examples thereof include sodium p-styrene sulfonate, sodium m-styrene sulfonate, sodium o-styrene sulfonate, calcium p-styrene sulfonate, calcium m-styrene sulfonate, calcium o-styrene sulfonate, ammonium p-styrene sulfonate, ammonium m-styrene sulfonate, ammonium o-styrene sulfonate, etc., preferably sodium styrene sulfonate, and more preferably sodium p-styrene sulfonate from the perspective of less steric hindrance in the reactivity with viruses.

[0055] At least one amino functional group selected from primary amino groups, secondary amino groups and tertiary amino groups or a salt of the amino functional group preferably forms a cyclic skeleton, preferably an alicyclic skeleton, from the perspective of improving the viral infection inhibitory effect of the viral infection inhibitor. The amino functional group or the salt of the amino functional group preferably constitutes a part of the alicyclic skeleton.

[0056] It should be noted that the primary amino group refers to a monovalent substituent represented by -NH2. The secondary amino group refers to a divalent substituent (-NH-) generated by removing one hydrogen atom (extraction) from -NH2. The tertiary amino group refers to a trivalent substituent [≡N, formula (a)] generated by removing two hydrogen atoms (extraction) from -NH2. Among them, with respect to the amino functional group, the case where a keto group (>CO) is directly bonded to the nitrogen atom constituting the amino functional group is not included. In formula (a), *1 to 3 refer to a bonding arm and are single bonds.

[0057] [Chemical formula 1]

[0058]

[0059] The salt of the amino functional group is not particularly limited, but is preferably an acid addition salt. Examples of the acid of the acid addition salt include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phosphorous acid, hydrobromic acid, maleic acid, malic acid, ascorbic acid, tartaric acid, lauric acid, stearic acid, palmitic acid, oleic acid, myristic acid, lauryl sulfuric acid, linolenic acid, and fumaric acid, and hydrochloride is preferred.

[0060] The virus infection inhibitory compound having an amino functional group or a salt thereof may have one or more amino functional groups or salts thereof in the molecule. Examples of the virus infection inhibitory compound having an amino functional group or a salt thereof in the molecule include polymers containing an amino functional group or a salt thereof on the side chain of a linear polymer.

[0061] Among the polymers containing an amino functional group or a salt thereof in the side chain of the linear polymer, the linear polymer is not particularly limited, and for example, a vinyl polymer and a polyester are preferred, and a vinyl polymer is more preferred.

[0062] Examples of the polymer containing an amino functional group or a salt thereof on the side chain of the linear polymer include a polymer containing an amino functional group-containing monomer containing an amino functional group or a salt thereof as a monomer unit, etc. In the polymer containing an amino functional group-containing monomer containing an amino functional group or a salt thereof as a monomer unit, the content of the amino functional group-containing monomer is preferably 50 mol% or more, more preferably 75 mol% or more, more preferably 90 mol% or more, more preferably 95 mol% or more, more preferably 99 mol% or more, and more preferably 100 mol%.

[0063] The amino functional group-containing monomer containing an amino functional group or a salt thereof is not particularly limited, and examples thereof include 2-vinylpyridine, 4-vinylpyridine, vinylimidazole, dimethylaminoethyl (meth)acrylate, diethylaminoethyl (meth)acrylate, tert-butylaminoethyl (meth)acrylate, N-(aminoalkyl)acrylamide, N-(aminoalkyl)methacrylamide, a monomer obtained by reacting ammonia, dimethylamine, etc. with glycidyl (meth)acrylate, allylamine, diallylamine, methyldiallylamine, 1,2,2,6,6-pentamethyl-4-piperidinyl methacrylate, 2,2,6,6-tetramethyl-4-piperidinyl methacrylate, or salts of these amino functional groups. It should be noted that the amino functional group-containing monomer containing an amino functional group or a salt thereof may be used alone or in combination of two or more.

[0064] The virus infection inhibitory compound having an amino functional group or a salt thereof in the molecule is not necessarily a polymer. Examples of the virus infection inhibitory compound having an amino functional group or a salt thereof in the molecule include chloromethylisothiazolinone, methylisothiazolinone, benzisothiazolinone, octylisothiazolinone, dichlorooctylisothiazolinone, bronopol, zinc pyrithione, benzalkonium chloride, didecyldimethylammonium, carbendazim, diuron, iodopropynylbutylcarbamate, and thiabendazole.

[0065] When the virus infection inhibitory compound is a polymer, it may be a homopolymer of a monomer having an infection inhibitory functional group (an infection inhibitory functional group-containing monomer) or a copolymer of the infection inhibitory functional group-containing monomer and a monomer copolymerizable with the infection inhibitory functional group-containing monomer.

[0066] The monomer copolymerizable with the infection-inhibiting functional group-containing monomer is not particularly limited, and examples thereof include alkyl acrylates, alkyl methacrylates, vinyl alkyl ethers, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, acrylamide, methacrylamide, diacetone acrylamide, vinyltoluene, etc. It should be noted that the monomer copolymerizable with the infection-inhibiting functional group-containing monomer may be used alone or in combination of two or more.

[0067] The polymer to be the virus infection inhibiting compound can be polymerized using a general polymerization method. For example, the virus infection inhibiting compound can be obtained by polymerizing a monomer composition containing a monomer containing an infection inhibiting functional group in the presence of a general free radical polymerization initiator. It should be noted that as the free radical polymerization initiator, there can be mentioned thermal cleavage type free radical polymerization initiators such as 1-hydroxycyclohexane-1-yl phenyl ketone, tert-hexyl peroxypivalate, benzoyl peroxide, and azobisisobutyronitrile.

[0068] As the virus infection inhibiting compound, there can be mentioned compounds having a guanidine structure in the molecule. The guanidine structure refers to a divalent atomic group having a structural formula represented by the following formula (b). It should be noted that *4 and *5 mean that the binding arms are single bonds.

[0069] [Chemical formula 2]

[0070]

[0071] As virus infection inhibitory compounds containing a guanidine structure in the molecule, for example, there can be mentioned a polymer having a structure represented by the following formula (1) (polyhexamethylene biguanide), an acid addition salt of a polymer having a structure represented by the following formula (2) (hydrochloride of polyhexamethylene biguanide), polyhexamethylene guanidine, polyhexamethylene guanidine hydrochloride, polyhexamethylene guanidine phosphate, etc., preferably an acid addition salt of a polymer having a structure represented by formula (1), and more preferably a hydrochloride of a polymer having a structure represented by formula (1) [formula (2)]. It should be noted that n means a repeating unit. n is a natural number greater than 2. x is a coefficient of the added hydrochloric acid. In polyhexamethylene biguanide, the content of the structure represented by formula (1) is preferably 80 mol% or more, more preferably 90 mol% or more, more preferably 95 mol% or more, more preferably 99 mol% or more, and more preferably 100 mol%. In the hydrochloride of polyhexamethylene biguanide, the content of the structure represented by formula (2) is preferably 80 mol% or more, more preferably 90 mol% or more, more preferably 95 mol% or more, more preferably 99 mol% or more, and more preferably 100 mol%.

[0072] [Chemical formula 3]

[0073]

[0074] [Chemical formula 4]

[0075]

[0076] The virus infection inhibitory compound containing at least one infection inhibitory functional group selected from the group consisting of carboxyl group, sulfonyl group, primary amino group, secondary amino group and tertiary amino group or a salt thereof, and the virus infection inhibitory compound containing a guanidine structure may be used in combination.

[0077] When the virus infection inhibitory compound contains a polymer, the weight average molecular weight of the polymer is preferably 1000 or more, more preferably 5000 or more, more preferably 10000 or more, and more preferably 100000 or more. When the weight average molecular weight of the virus infection inhibitory compound is 1000 or more, the yellowing resistance of the virus infection inhibitor can be improved, and when the virus infection inhibitor is attached to the surface of the substrate, the appearance of the substrate can be not damaged, and the virus infection inhibitory effect can be more effectively exhibited. At the same time, the adsorption points of the virus per molecule of the virus infection inhibitory compound can be increased, the interaction between the virus infection inhibitory compound and the virus becomes stronger, and the virus infection inhibitory effect of the virus infection inhibitor is improved.

[0078] The weight average molecular weight of the polymer contained in the virus infection inhibitory compound is preferably 1500000 or less, more preferably 1000000 or less, more preferably 900000 or less, more preferably 800000 or less, and more preferably 500000 or less. When the weight average molecular weight of the virus infection inhibitory compound is 1500000 or less, the yellowing resistance of the virus infection inhibitor can be improved, and when the virus infection inhibitor is attached to the surface of the substrate, the appearance of the substrate can be not damaged, and the virus infection inhibitory effect can be more effectively exhibited, while at the same time reducing the cohesion of the virus infection inhibitor and improving the coating property.

[0079] In addition, in this invention, the weight average molecular weight of a polymer is the value measured by GPC (gel permeation chromatography) method and is converted into polystyrene.

[0080] For example, the measurement can be performed using the following measuring apparatus and measuring conditions.

[0081] Gel Permeation Chromatograph: Waters Corporation, trade name "2690 Separations Model"

[0082] Column: Showa Denko K.K. trade name "GPC KF-806L"

[0083] Detector: Differential Refractometer

[0084] Sample flow rate: 1mL / min

[0085] Column temperature: 40°C

[0086] Eluent: THF

[0087] The virus infection inhibition compound is preferably formed into a particle shape. The D90 particle size of the virus infection inhibition compound is preferably 2 μm or more, more preferably 2.5 μm or more, more preferably 3 μm or more, and more preferably 3.5 μm or more. The D90 particle size of the virus infection inhibition compound is preferably 25 μm or less, more preferably 22 μm or less, more preferably 20 μm or less, more preferably 18 μm or less, more preferably 16 μm or less, more preferably 14 μm or less, and more preferably 12 μm or less. When the D90 particle size is 2 μm or more, the overall surface area of ​​the virus infection inhibition compound becomes smaller, the cohesion of the virus infection inhibitor is reduced and the coating property is improved, the virus infection inhibition compound and the virus become in a form that is easy to interact with each other, and the virus infection inhibition effect of the virus infection inhibitor is improved. When the D90 particle size is less than 25 μm, the aggregation of the viral infection inhibitor can be prevented and the surface area is increased to facilitate contact with viruses, thereby improving the viral infection inhibition effect of the viral infection inhibitor. At the same time, visible light scattering is easy to occur, which can inhibit the discoloration of the viral infection inhibition compound and improve the yellowing resistance of the viral infection inhibitor. In addition, the number of coarse particles is reduced, thereby improving the coating properties of the viral infection inhibitor.

[0088] As described below, the D90 particle size of the virus infection inhibiting compound is the particle size (90% cumulative particle size) at which the accumulation of frequencies in the volume-based particle size distribution based on the laser scattering method (accumulation of particles with smaller particle sizes) becomes 90%. By adjusting the D90 particle size of the virus infection inhibiting compound to the above range, the particle size of particles with larger particle sizes in the virus infection inhibiting compound is adjusted to a given range, thereby reducing the presence of coarse particles in the virus infection inhibiting compound. The virus infection inhibiting compound has an infection inhibiting functional group on its surface. By adjusting the particle size of the virus infection inhibiting compound to the above range, the amount of infection inhibiting functional groups or guanidine structures present on the surface of the virus infection inhibiting compound can be adjusted, thereby imparting an excellent virus infection inhibiting effect to the virus infection inhibitor, while at the same time reducing the interaction in the infection inhibiting functional group and / or guanidine structure and improving the yellowing resistance of the virus infection inhibitor.

[0089] The D50 particle size of the virus infection inhibiting compound is preferably 0.5 μm or more, more preferably 1 μm or more, more preferably 1.5 μm or more, more preferably 2.0 μm or more. The D50 particle size of the virus infection inhibiting compound is preferably 14 μm or less, more preferably 12 μm or less, more preferably 11 μm or less.

[0090] In the virus infection inhibiting compound, by setting the D50 particle size and the D90 particle size within the above ranges, the presence of coarse particles having a particle size greatly deviating from the D50 particle size in the virus infection inhibiting compound can be reduced, and the particle size of the virus infection inhibiting compound can be made more appropriate.

[0091] Furthermore, by adjusting the particle size of the viral infection inhibitory compound to a more appropriate range, the amount of infection inhibitory functional groups and guanidine structures present on the surface of the viral infection inhibitory compound can be more appropriately adjusted, thereby more effectively imparting an excellent viral infection inhibitory effect to the viral infection inhibitor. At the same time, visible light scattering is easily generated, thereby suppressing the discoloration of the viral infection inhibitory compound, thereby improving the yellowing resistance of the viral infection inhibitor. In addition, the number of coarse particles is reduced, thereby improving the coating properties of the viral infection inhibitor.

[0092] The D90 particle size and D50 particle size of the virus infection inhibitory compound refer to the particle sizes (90% cumulative particle size and 50% cumulative particle size) at which the accumulation of frequencies in the volume-based particle size distribution based on the laser scattering method (accumulation of particles with smaller particle sizes) reaches 90% and 50%, respectively. In the case where the virus infection inhibitory compound contains a plurality of virus infection inhibitory compounds, the D90 particle size and D50 particle size of the virus infection inhibitory compound are values ​​measured based on the virus infection inhibitory compound as a whole.

[0093] [Carrier]

[0094] The virus infection inhibitor comprises the virus infection inhibitor compound, wherein the virus infection inhibitor compound is supported on a substrate having a specific surface area of ​​1 to 1000 m 2 / g of carrier.

[0095] Specific surface area is 1~1000m 2 / g of the carrier has a fine pore structure, and a portion of the virus infection inhibitory compound can be allowed to enter the pore structure to prevent the virus infection inhibitory compound from falling off the carrier surface, thereby forming a structure that can stably maintain the virus infection inhibitory effect of the virus infection inhibitor for a long time.

[0096] In addition, by allowing the virus infection inhibitory compound to be supported on a pore structure of a carrier having a specific surface area within a given range, the interaction between the infection inhibitory functional groups and / or guanidine structures possessed by the virus infection inhibitory compound can be reduced, thereby improving the yellowing resistance of the virus infection inhibitor. At the same time, the cohesion of the virus infection inhibitor can be reduced and the coating property can be improved.

[0097] In addition, by attaching the virus infection inhibitor compound to the surface of a carrier having a given specific surface area, the virus infection inhibitor can be uniformly dispersed on the underlying substrate without forming a mass. Therefore, the surface area of ​​the virus infection inhibitor can be increased, the contact between the virus infection inhibitor and the virus can be fully ensured, and the virus infection inhibitor can fully exert its virus infection inhibitory effect.

[0098] The carrier for attaching the virus infection inhibiting compound to the surface is not particularly limited as long as it does not hinder the virus infection inhibiting effect of the virus infection inhibitor. The particles include resin particles and inorganic particles. The particles can be used alone or in combination of two or more.

[0099] Examples of the synthetic resin constituting the resin particles include styrene resins, acrylic resins, polyurethane resins, vinyl chloride resins, ABS resins, and synthetic rubbers such as styrene-butadiene rubber (SBR) and nitrile rubber (NBR). Styrene resins are preferred, and polystyrene is more preferred.

[0100] The styrene-based resin is not particularly limited, and examples thereof include homopolymers or copolymers containing a styrene-based monomer such as styrene, methylstyrene, ethylstyrene, isopropylstyrene, dimethylstyrene, chlorostyrene, bromostyrene, etc. as a monomer unit, and copolymers containing a styrene-based monomer and one or more vinyl monomers copolymerizable with the styrene-based monomer as a monomer unit.

[0101] Examples of the vinyl monomer copolymerizable with the styrene-based monomer include acrylic monomers such as acrylonitrile, methacrylonitrile, acrylic acid, methacrylic acid, acrylic acid esters (methyl acrylate, ethyl acrylate, butyl acrylate, etc.), methacrylate esters (methyl methacrylate, ethyl methacrylate, butyl methacrylate, etc.), maleic anhydride, and acrylamide.

[0102] The acrylic resin is not particularly limited, and examples thereof include homopolymers or copolymers containing acrylic monomers such as methyl (meth)acrylate, ethyl (meth)acrylate, butyl (meth)acrylate, and pentyl (meth)acrylate as monomer units, and copolymers containing acrylic monomers and one or more vinyl monomers copolymerizable with the acrylic monomer as monomer units. It should be noted that (meth)acrylate means acrylic acid ester or methacrylic acid ester.

[0103] Examples of the vinyl monomer copolymerizable with the acrylic monomer include acrylonitrile, methacrylonitrile, maleic anhydride, and acrylamide.

[0104] The inorganic material constituting the inorganic particles is not particularly limited, and examples thereof include silica, zeolite, diatomaceous earth, kaolin, hydrotalcite, calcium carbonate, calcium citrate, magnesium carbonate, aluminum hydroxide, magnesium hydroxide, titanium oxide, and talc.

[0105] The synthetic resin constituting the resin particles preferably contains an aromatic ring. The aromatic ring attracts the hydrophobic portion of the virus infection inhibitory compound attached to the surface of the resin particles, plays a role in orienting the infection inhibitory functional group and the guanidine structure outward, and can more effectively exert the virus infection inhibitory effect of the virus infection inhibitor.

[0106] The aromatic ring may be a monocyclic aromatic ring or a monocyclic aromatic ring compounded and fused (fused aromatic ring). The aromatic ring is not particularly limited, and examples thereof include a benzene ring, a naphthalene ring, an anthracene ring, a biphenyl ring, and a phenoxyphenyl ring. Any one or more hydrogen atoms in the aromatic ring and the fused aromatic ring of the aromatic ring are removed and bonded to other atoms through covalent bonds.

[0107] The mass ratio of the virus infection inhibition compound to the carrier (mass of the virus infection inhibition compound / mass of the carrier) is preferably 0.01 or more, more preferably 0.02 or more, more preferably 0.05 or more, more preferably 0.07 or more, more preferably 0.1 or more, more preferably 0.2 or more, and more preferably 0.25 or more. The mass ratio of the virus infection inhibition compound to the carrier (mass of the virus infection inhibition compound / mass of the carrier) is preferably 10 or less, more preferably 7 or less, more preferably 5 or less, and more preferably 4 or less. When the mass ratio of the virus infection inhibition compound to the carrier (mass of the virus infection inhibition compound / mass of the carrier) is 0.05 or more, the virus infection inhibitor can be uniformly attached to the surface of the carrier, the virus infection inhibitor can be more effectively exerted, and the virus infection inhibitor can be uniformly dispersed in the coating without agglomeration, and the virus infection inhibitor has excellent coating properties. When the mass ratio of the virus infection inhibition compound to the carrier (mass of the virus infection inhibition compound / mass of the carrier) is 10 or less, the virus infection inhibition compounds do not bind to each other, and the virus infection inhibitor is efficiently configured on the surface of the resin particles, which can improve the virus infection inhibition effect and improve the yellowing resistance of the virus infection inhibitor.

[0108] There is no particular limitation on the method for loading the virus infection inhibitory compound on the surface of the carrier. For example, the virus infection inhibitory compound can be loaded by the adhesive force of the virus infection inhibitory compound, or the virus infection inhibitory compound can be bonded to the surface of the carrier using an adhesive resin. From the perspective of being able to effectively exert the virus infection inhibitory effect of the virus infection inhibitor, it is preferred to attach the virus infection inhibitory compound to the surface of the carrier by the adhesive force of the virus infection inhibitory compound itself.

[0109] The specific surface area of ​​the support is 1m 2 / g or more, preferably 50m 2 / g or more, more preferably 100m 2 / g or more, more preferably 200m2 / g or more. The specific surface area of ​​the support is 1000m 2 / g or less, preferably 800m 2 / g or less, preferably 700m 2 / g or less, more preferably 600m 2 / g or less, more preferably 500m 2 / g or less, preferably 400m 2 / g or less. The specific surface area of ​​the support is 1m 2 When the surface area of ​​the carrier is 1000 m 2 When the content is less than 1.1477 W / g, the interaction between supports can be reduced, the contact between the virus infection inhibitor and the virus can be increased, the virus infection inhibitor's virus infection inhibitor effect can be increased, and the aggregation of the virus infection inhibitor can be reduced to improve coating properties.

[0110] In addition, the specific surface area of ​​the support refers to a value measured by the BET method based on JIS Z8830.

[0111] The D50 particle size of the support is preferably 0.1 μm or more, more preferably 0.2 μm or more, more preferably 1 μm or more, and more preferably 2 μm or more. The D50 particle size of the support is preferably 200 μm or less, more preferably 100 μm or less, more preferably 80 μm or less, more preferably 60 μm or less, more preferably 40 μm or less, more preferably 20 μm or less, and more preferably 10 μm or less.

[0112] When the D50 particle size of the carrier is 0.1 μm or more, the virus infection inhibitor compound can be dispersed and carried in the pore structure of the carrier, which can improve the contact between the virus infection inhibitor and the virus and improve the virus infection inhibitor effect. In addition, the virus infection inhibitor is efficiently configured on the surface of the resin particles without combining the virus infection inhibitor compounds with each other, which can improve the virus infection inhibitor effect and improve the yellowing resistance of the virus infection inhibitor.

[0113] When the D50 particle size of the carrier is 200 μm or less, visible light scattering occurs easily, and discoloration of the virus infection inhibitor compound can be suppressed, thereby improving the yellowing resistance of the virus infection inhibitor. In addition, the number of coarse particles is reduced, thereby improving the coating properties of the virus infection inhibitor.

[0114] The D50 particle size of the support refers to the particle size (50% cumulative particle size) at which the cumulative frequency (derived from the cumulative frequency of particles with smaller particle sizes) in the volume-based particle size distribution based on the laser scattering method is 50%. When the support includes multiple supports, the D50 particle size of the support is a value measured based on the entire support.

[0115] [Viral infection inhibitors]

[0116] The virus infection inhibitor comprises a carrier having a specific surface area within a given range and a given virus infection inhibitor compound supported by the carrier. The method for producing the virus infection inhibitor is not particularly limited, and the virus infection inhibitor can be produced by supporting the virus infection inhibitor compound on the carrier by a general method.

[0117] In the viral infection inhibitor, the total amount of the carrier and the viral infection inhibitory compound carried by the carrier is preferably 50 mass% or more, more preferably 60 mass% or more, more preferably 70 mass% or more, more preferably 80 mass% or more, more preferably 90 mass% or more, more preferably 95 mass% or more, and more preferably 99 mass% or more.

[0118] The virus infection inhibitor has a virus infection inhibitory effect on various viruses through the action of the virus infection inhibitory compound, and exhibits an excellent virus infection inhibitory effect on both enveloped viruses and non-enveloped viruses.

[0119] Examples of enveloped viruses include influenza virus (e.g., type A, type B, etc.), rubella virus, Ebola virus, coronavirus [e.g., SARS virus, novel coronavirus (SARS-CoV-2)], measles virus, varicella-zoster virus, herpes simplex virus, mumps virus, arbovirus, RS virus, hepatitis virus (e.g., hepatitis B virus, hepatitis C virus, etc.), yellow fever virus, HIV, rabies virus, Hanta virus, dengue virus, Nipah virus, lyssa virus, etc.

[0120] Examples of the non-enveloped virus include feline calicivirus, adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, and rhinovirus.

[0121] The viral infection inhibitor can be contained in a base material to be imparted with a viral infection inhibitory effect and used, and the base material containing the viral infection inhibitor can express the viral infection inhibitory effect as a viral infection inhibitory product.

[0122] Furthermore, since the viral infection inhibitor has excellent yellowing resistance, the substrate containing the viral infection inhibitor does not undergo yellowing due to the viral infection inhibitor, and the original appearance of the substrate can be maintained for a long time.

[0123] The substrate containing the viral infection inhibitor is not particularly limited as long as it can contain the viral infection inhibitor, and examples thereof include synthetic resin moldings, coatings, wallpapers, decorative sheets, flooring materials, fiber products (woven fabrics, non-woven fabrics, knitted fabrics), interior products and interior materials (seats, child seats and foams constituting them, etc.) for vehicles (such as cars, airplanes, ships, etc.), kitchen supplies, baby products, and building interior materials.

[0124] The synthetic resin constituting the synthetic resin molded body is not particularly limited, and examples thereof include thermoplastic resins (e.g., polyethylene, polypropylene, polyvinyl chloride, polystyrene, polyvinyl acetate, polyurethane, TEFLON (registered trademark), acrylonitrile butadiene styrene resin, acrylonitrile styrene resin, acrylic resin, polyvinyl alcohol, polyamide, polyacetal, polycarbonate, modified polyphenylene ether, polyester, polyethylene terephthalate, polybutylene terephthalate, cyclic polyolefin, polyphenylene sulfide, polytetrafluoroethylene, polysulfone, polyether sulfone, polyarylate, polyether ether ketone, thermoplastic polyimide, polyamide-imide, etc.), thermosetting resins (e.g., phenolic resin, epoxy resin, melamine resin, urea resin, unsaturated polyester resin, alkyd resin, polysiloxane resin, polyurethane, thermosetting polyimide, etc.), etc. It should be noted that the synthetic resins may be used alone or in combination of two or more.

[0125] The virus infection inhibitor can be mixed with a synthetic resin for use. As a method for mixing the virus infection inhibitor with a synthetic resin, the virus infection inhibitor can be mixed with a synthetic resin as a raw material to prepare a resin composition, and the resin composition is used to obtain a virus infection inhibition product of a desired shape as a molded product by a general synthetic resin molding method. As a general synthetic resin molding method, for example, extrusion molding, injection molding, blow molding, etc. can be cited. It is also possible to make a synthetic resin molding masterbatch containing a synthetic resin and a virus infection inhibitor, mix it with a synthetic resin as a raw material, and use a general synthetic resin molding method as a molded product to manufacture a virus infection inhibition product.

[0126] In the viral infection inhibiting product, the content of the viral infection inhibitor is preferably 0.5 parts by mass or more, more preferably 1 part by mass or more, and more preferably 2 parts by mass or more, relative to 100 parts by mass of the substrate. In the viral infection inhibiting product, the content of the viral infection inhibitor is preferably 20 parts by mass or less, more preferably 10 parts by mass or less, and more preferably 7 parts by mass or less, relative to 100 parts by mass of the substrate.

[0127] [Masterbatch for synthetic resin molding]

[0128] The masterbatch for synthetic resin molding comprises a synthetic resin and a virus infection inhibitor. The synthetic resin can be used alone or in combination of two or more. As the synthetic resin, it can be a thermoplastic resin or a thermosetting resin, preferably a thermoplastic resin. As the thermoplastic resin, polyolefin resin, polyvinyl chloride resin, polyamide resin, polycarbonate resin, polystyrene resin, polyester resin, acrylonitrile-butadiene-styrene resin (ABS resin), polyethylene terephthalate (PET), polyurethane resin and polymethyl methacrylate (PMMA) etc. can be cited.

[0129] The content of the synthetic resin in the synthetic resin molding masterbatch is preferably 10% by mass or more, more preferably 20% by mass or more. The content of the synthetic resin in the synthetic resin molding masterbatch is preferably 80% by mass or less, more preferably 60% by mass or less.

[0130] The content of the virus infection inhibitor in the synthetic resin molding masterbatch is preferably 10% by mass or more, more preferably 15% by mass or more. The content of the virus infection inhibitor in the synthetic resin molding masterbatch is preferably 80% by mass or less, more preferably 70% by mass or less.

[0131] The resin composition, in particular the masterbatch for synthetic resin molding, preferably further contains a surfactant. The surfactant is not particularly limited, and examples thereof include anionic surfactants, cationic surfactants, nonionic surfactants, amphoteric surfactants, etc., preferably anionic surfactants and nonionic surfactants. In the case where the masterbatch for synthetic resin molding further contains a surfactant, the virus infection inhibition compound can be easily segregated on the surface of the obtained virus infection inhibition product (molded body), further improving the virus infection inhibition effect of the virus infection inhibition product (molded product).

[0132] The anionic surfactant is not particularly limited, and examples thereof include alkyl phosphates such as sodium dodecyl phosphate, potassium dodecyl phosphate, sodium stearyl phosphate, potassium stearyl phosphate, polyoxyethylene (3) lauryl ether sodium phosphate, polyoxyethylene (3) lauryl ether potassium phosphate, polyoxyethylene alkyl ether phosphates such as sodium polyoxyethylene (3) lauryl ether phosphate, polyoxyethylene (3) lauryl phenyl ether sodium phosphate, polyoxyethylene (3) lauryl phenyl ether potassium phosphate, alkylbenzene sulfonates (e.g., sodium dodecylbenzene sulfonate, potassium dodecylbenzene sulfonate, ammonium dodecylbenzene sulfonate, triethanolammonium dodecylbenzene sulfonate, etc.), α-olefin sulfonates, alkyl diphenyl ether sulfonates, polyoxyalkylene alkyl ether sulfates, and the like are preferred. Alkylbenzene sulfonates are preferred.

[0133] The nonionic surfactant is not particularly limited, and examples thereof include polyoxyalkylene alkyl ethers, polyoxyethylene alkyl ethers, polyoxyethylene alkylphenyl ethers, polyoxyethylene fatty acid esters (e.g., polyethylene glycol distearate), polyoxyethylene distyrenated phenyl ethers, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitol fatty acid esters, glycerol fatty acid esters, polyoxyethylene glycerol fatty acid esters, polyglycerol fatty acid esters, sucrose fatty acid esters, polyoxyethylene alkylamines, polyoxyethylene fatty acid amides, fatty acid alkanolamides (e.g., coconut oil fatty acid dimethanolamide, coconut oil fatty acid diethanolamide, coconut oil fatty acid dipropanolamide and other coconut oil fatty acid alkanolamides), fatty acid alkylolamides, alkyl alkanolamides, acetylene glycol, ethylene oxide addition products of acetylene glycol, polyethylene glycol polypropylene glycol block copolymers, and the like are preferably polyoxyethylene distyrenated phenyl ethers, polyoxyethylene fatty acid esters, and fatty acid alkanolamides.

[0134] The amphoteric surfactant is not particularly limited, and examples thereof include alkylaminoacetic acid betaine, alkylamidopropyl betaine, sulfobetaine, alkylamino (mono or di) propionate, imidazolinium betaine, alkylamine oxide, alkylaminoethylglycine, alkyldi(aminoethyl)glycine, glycine n-(3-aminopropyl) C10-16 derivative, alkylpolyaminoethylglycine, alkylβ-alanine, alkyldiethanolamine, polyoxyalkylenealkylamine, and diamine oxyethylene addition type surfactants.

[0135] The content of the surfactant in the resin composition is preferably 0.1% by mass or more, more preferably 1% by mass or more. The content of the surfactant in the resin composition is preferably 40% by mass or less, more preferably 30% by mass or less.

[0136] The virus infection inhibitor used in the resin composition, especially the masterbatch for synthetic resin molding, preferably contains an antioxidant. By containing an antioxidant in the virus infection inhibitor, the yellowing of the synthetic resin during the molding process using the masterbatch for synthetic resin molding or the obtained molded product (virus infection inhibition product) can be reduced.

[0137] The antioxidant is not particularly limited, and examples thereof include monophenol antioxidants, bisphenol antioxidants, amine antioxidants, phosphorus antioxidants, sulfur antioxidants, etc., preferably phenol antioxidants and bisphenol antioxidants. It should be noted that the antioxidants may be used alone or in combination of two or more.

[0138] Examples of the monophenol antioxidant include butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), octadecyl-3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate, 2,2'-methylenebis(4-methyl-6-tert-butylphenol), 2-tert-butyl-6-(3-tert-butyl-2-hydroxy-5-methylbenzyl)-4-methylphenyl acrylate, 2-[1-(2-hydroxy-3,5-di-tert-pentylphenyl)ethyl]-4,6-di-tert-pentylphenyl acrylate, 4,4'-butylenebis(3 -methyl-6-tert-butylphenol), 4,4'-thiobis(3-methyl-6-tert-butylphenol), tetrakis[methylene-3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate]methane, 3,9-bis[2-(3-(3-tert-butyl-4-hydroxy-5-methylphenyl)-propionyloxy)-1,1-dimethylethyl]-2,4,8,10-tetraoxaspiro[5,5]undecane, etc., preferably butylated hydroxytoluene (BHT) and dibutylhydroxyanisole (BHA) because the obtained molded article has excellent yellowing resistance.

[0139] Examples of bisphenol antioxidants include 2,2'-methylenebis(4-methyl-6-tert-butylphenol), 2,2'-methylenebis(4-ethyl-6-tert-butylphenol), 4,4'-thiobis(3-methyl-6-tert-butylphenol), 4,4'-butylenebis(3-methyl-6-tert-butylphenol), 3,9-bis[1,1-dimethyl-2-[β-(3-tert-butyl-4-hydroxy-5 [-methylphenyl)propionyloxy]ethyl]2,4,8,10-tetraoxaspiro[5.5]undecane, 2,2'-dihydroxy-3,3'-di(α-methylcyclohexyl)-5,5'-dimethyldiphenylmethane, etc., and 2,2'-methylenebis(4-methyl-6-tert-butylphenol) and 4,4'-thiobis(3-methyl-6-tert-butylphenol) are preferred because the resulting molded article has excellent yellowing resistance.

[0140] The melting point of the antioxidant is preferably below 200°C, more preferably below 170°C, and more preferably below 100°C. The melting point of the antioxidant is preferably above 50°C, and more preferably above 60°C. When the melting point of the antioxidant is below 200°C, the antioxidant is melted during the molding process using the synthetic resin molding masterbatch, and the mixing degree of the virus infection inhibitor containing the antioxidant and the synthetic resin becomes higher, which can reduce the yellowing of the synthetic resin during the molding process or the obtained molded product (virus infection inhibition product). When the melting point of the antioxidant is above 50°C, it is preferred because the operability of the virus infection inhibitor containing the antioxidant at room temperature is improved. It should be noted that the melting point of the antioxidant refers to the temperature measured based on JIS K0064:1992.

[0141] The content of the antioxidant in the viral infection inhibitor is preferably 0.1% by mass or more, more preferably 1% by mass or more. The content of the surfactant in the viral infection inhibitor is preferably 5% by mass or less, more preferably 4% by mass or less.

[0142] The synthetic resin molding masterbatch is preferably a resin pellet because of its excellent moldability. The resin pellets can be melted and molded to obtain a virus infection inhibiting product (molded product) having an excellent virus infection inhibiting effect.

[0143] The shape of the resin particles is not particularly limited, and spherical, cylindrical, and prismatic shapes can be cited. From the perspective of the stability of the particle shape, a cylindrical shape is preferred. The maximum length direction of the resin particles is preferably 1 mm or more, more preferably 3 mm or more. The maximum length direction of the resin particles is preferably 10 mm or less, more preferably 7 mm or less.

[0144] The synthetic resin molding masterbatch can be mixed with other resin materials for use. The other resin materials can be resin particles. After the synthetic resin molding masterbatch and the other resin materials are mixed to obtain a mixed resin material, the mixed resin material is molded to obtain a virus infection inhibition product (molded product) with excellent virus infection inhibition effect.

[0145] As the coating material, conventionally known coating materials can be used, for example, oil-based coating materials (such as prepared coating materials and oil varnishes), cellulose coating materials, synthetic resin coating materials, etc. The coating material also includes photocurable coating materials that polymerize upon exposure to radiation such as ultraviolet rays to generate a binder component.

[0146] Since the virus infection inhibitor has excellent coating properties, the virus infection inhibitor can be uniformly dispersed in the coating material, and the coating film formed from the coating material can exert a virus infection inhibitory effect that is generally uniform as a whole.

[0147] Since the virus infection inhibitor has excellent yellowing resistance, the coating film formed by the paint containing the virus infection inhibitor does not yellow for a long time. Therefore, the article having the coating film formed on the surface can maintain its appearance for a long time.

[0148] The coating may contain additives such as pigments, plasticizers, curing agents, extenders, fillers, anti-aging agents, thickeners, surfactants, etc., within the range that does not impair its physical properties. It should be noted that as a method for making the coating contain a viral infection inhibitor, for example, a method of supplying the viral infection inhibitor and the coating to a dispersing device and uniformly mixing them can be cited. It should be noted that as a dispersing device, for example, a high-speed mill, a ball mill, a sand mill, etc. can be cited.

[0149] The building interior material is not particularly limited, and examples thereof include floor materials, wallpapers, ceiling materials, paints, door handles, switches, switch covers, wax, and the like.

[0150] The vehicle interior products and vehicle interior materials are not particularly limited, and examples thereof include seats, child seats, seat belts, car mats, seat covers, doors, roof materials, floor mats, door trims, instrument panels, consoles, glove boxes, hanging rings, armrests, and the like.

[0151] Example

[0152] Hereinafter, the present invention is more specifically described using Examples, but the present invention is not limited thereto.

[0153] As virus infection inhibiting compounds, polymers 1 to 10, citric acid, N-[1-[2-(dodecylamino)ethylamino]ethyl]glycine and N-[1-[2-(dodecylamino)ethylamino]ethyl]glycine hydrochloride were prepared. When the virus infection inhibiting compound is a polymer, the weight average molecular weight is as shown in the "weight average molecular weight" column of Tables 1 to 3. The molecular weight of citric acid is recorded in the "weight average molecular weight" column for convenience. The "guanidine structure" of the virus infection inhibiting compound is recorded in the "virus infection inhibiting functional group" column for convenience.

[0154] [Viral infection inhibitory compounds]

[0155] Polymer 1 (polystyrene sulfonic acid, formula (3), trade name "Versa-TL72" manufactured by Nouryon)

[0156] Polymer 2 (polyacrylic acid, formula (4), trade name "HL-415" manufactured by NIPPON SHOKUBAI CO., LTD.)

[0157] Citric acid

[0158] Polymer 3 (polyallylamine, formula (5), trade name "PAA-15C" manufactured by NITTOBO-NMD Co., Ltd.)

[0159] Polymer 4 (diallylamine hydrochloride polymer, formula (6), trade name "PAS-21CL" manufactured by NITTOBO-NMD Co., Ltd.)

[0160] Polymer 5 (diallylamine polymer, formula (7), trade name "PAS-21" manufactured by NITTOBO-NMD Co., Ltd.)

[0161] Polymer 6 (a copolymer of allylamine hydrochloride and diallylamine hydrochloride, formula (8), trade name "PAA-D19-JCl" manufactured by NITTOBO-NMD Co., Ltd.)

[0162] Polymer 7 (copolymer of diallylamine hydrochloride and maleic acid, formula (9), trade name "PAS-410C" manufactured by NITTOBO-NMD Co., Ltd.)

[0163] Polymer 8 (copolymer of diallylamine hydrochloride and maleic acid, formula (9), trade name "PAS-411C" manufactured by NITTOBO-NMD Co., Ltd.)

[0164] Polymer 9 (methyldiallylamine hydrochloride polymer, formula (10), trade name "PAS-M-1" manufactured by NITTOBO-NMD Co., Ltd.)

[0165] Polymer 10 (hydrochloride of polyhexamethylene biguanide, formula (2), trade name "VA NTOCILTG" of LONZA)

[0166] N-[1-[2-(Dodecylamino)ethylamino]ethyl]glycine (trade name "LEBON S" manufactured by Sanyo Chemical Co., Ltd.) (in the table, described as "dodecylaminoethylaminoethylglycine.")

[0167] ·N-[1-[2-(Dodecylamino)ethylamino]ethyl]glycine hydrochloride (trade name "LEBON T-2" manufactured by Sanyo Chemical Co., Ltd.) (in the table, described as "dodecylaminoethylaminoethylglycine hydrochloride.")

[0168] [Chemical formula 5]

[0169]

[0170] In formulae (3) to (10), n, m and p represent repeating units and are natural numbers of 2 or more.

[0171] [Chemical formula 6]

[0172]

[0173] In the structural formula shown above, the structural formula shown in formula (11) means a random copolymer, an alternating copolymer or a block copolymer of monomer units M1 and M2. n, m and p represent repeating units and are natural numbers greater than 2. In formulas (1) to (11), n, m and p only mean repeating units. In formulas (1) to (11), n, m and p are respectively independent values. In formula (2), x is the coefficient of the hydrochloric acid added.

[0174] [Chemical formula 7]

[0175]

[0176] [Carrier (particles)]

[0177] Silica particles 1 (product name: "SYLOSPHERE C-1504" manufactured by FUJI SILYSIA)

[0178] Silica particles 2 (trade name "SO-C1" manufactured by ADMATECHS)

[0179] Silica particles 3 (trade name "SO-C6" manufactured by ADMATECHS)

[0180] Silica particles 4 (product name: SYLYSIA250, manufactured by FUJI SILYSIA)

[0181] Silica particles 5 (product name: SYLYSIA730, manufactured by FUJI SILYSIA)

[0182] Silica particles 6 (trade name "SUNSPHERE H-51" manufactured by AGC SI-TECH)

[0183] Zeolite particles (manufactured by TOSOH, trade name "930NHA")

[0184] Diatomaceous earth particles (trade name "RADIOLITE 100" manufactured by Hayashi Chemical Industry Co., Ltd.)

[0185] Kaolin particles (trade name "Satintone 5HB" manufactured by BASF)

[0186] Calcium carbonate particles 1 (trade name "ESCALON #200" manufactured by Sankyo Seikan Co., Ltd.)

[0187] Calcium carbonate particles 2 (trade name "Escalon (A)" manufactured by Sankyo Seikan Co., Ltd.)

[0188] Talc particles (trade name "MICRO ACE P-8" manufactured by TALC Japan)

[0189] Aluminum hydroxide particles (Showa Denko K.K. trade name "A-43-L")

[0190] Titanium oxide particles (trade name "PT-301" manufactured by Ishihara Sangyo Co., Ltd.)

[0191] ·Hydrotalcite particles 1(Mg4Al2(OH) 12 CO3·3H2O, Mg-Al type, manufactured by SAKAI-CHEM Co., Ltd. (trade name "HT-1")

[0192] Hydrotalcite particles 2(Mg6Al2(OH) 16CO3·mH2O, Mg-Al type, manufactured by SAKAI-CHEM Co., Ltd. (trade name "HT-6")

[0193] ·Hydrotalcite particles 3(Mg 4.5 Al2(OH) 13 CO3·3.5H2O, Mg-Al type, manufactured by SAKAI-CHEM Co., Ltd. (trade name "HT-P")

[0194] ·Hydrotalcite particles 4(Mg 3.5 Zn 0.5 Al2(OH) 12 CO3·3H2O, Mg-Zn-Al type, manufactured by SAKAI-CHEM Co., Ltd. (trade name "HT-7")

[0195] Acrylic resin particles 1 (trade name "MBP-8HP" manufactured by Sekisui Chemicals Co., Ltd.)

[0196] Acrylic resin particles 2 (trade name "MBP-8" manufactured by Sekisui Chemicals Co., Ltd.)

[0197] [Antioxidant]

[0198] [Monophenolic antioxidants]

[0199] Butylated hydroxytoluene (BHT)

[0200] Butylated hydroxyanisole (BHA)

[0201] [Bisphenol antioxidants]

[0202] · Bisphenol antioxidant 1 (2,2'-methylenebis(4-methyl-6-tert-butylphenol), manufactured by Ouchi Shinko Chemical Industry Co., Ltd., trade name "NOCRAC NS-6")

[0203] · Bisphenol antioxidant 2 (4,4'-thiobis(3-methyl-6-tert-butylphenol), manufactured by Ouchi Shinko Chemical Industry Co., Ltd., trade name "NOCRAC 300")

[0204] (Examples 1 to 31, Comparative Example 11)

[0205] Water having a mass of 7 times the total mass of the virus infection inhibiting compound and the carrier is prepared. The virus infection inhibiting compound and the carrier (particles) of the types shown in Tables 1 and 2 are supplied to water and uniformly mixed to prepare a dispersion. The particles used in the carrier have a D50 particle size and a specific surface area shown in Tables 1 and 2. The mass ratio of the virus infection inhibiting compound to the carrier supplied to water (mass of the virus infection inhibiting compound / mass of the carrier) is shown in the "Compound / Carrier" column of Tables 1 and 2.

[0206] Next, the dispersion is powdered using a spray dryer through an atomizer at a rotation speed of 20,000 rpm, so that the total amount of the virus infection inhibitory compound is attached (loaded) to the surface of the carrier, and then pulverized using a jet mill device (trade name "SJ-500" manufactured by NISSHIN ENGINEERING Co., Ltd.) under operating conditions of a raw material supply rate of 1 kg / h and a compressed air pressure of 0.75 MPa to obtain a carrier on which the virus infection inhibitory compound has been loaded (attached) to the surface as a virus infection inhibitor.

[0207] A coating composition (a viral infection inhibitor product) was prepared by mixing 5 parts by mass of the viral infection inhibitor shown in Tables 1 and 2 with 95 parts by mass of an ultraviolet curable acrylic coating (trade name "AI-N2" manufactured by COATTECH). The coating composition was applied to a polyethylene film with a wire rod coater #8 to a thickness of 18 μm to form a coating layer.

[0208] A UV conveyor device ("ECS301G1" manufactured by Eye Graphics) was used to apply light to the coating layer at 25°C with a cumulative light dose of 500 mJ / cm 2 The ultraviolet curing acrylic coating was cured by irradiating ultraviolet rays with a wavelength of 365 nm to form a coating film with a thickness of 18 μm.

[0209] (Comparative Example 1)

[0210] The virus infection inhibiting compound shown in the column of "Type" in Table 2 is used without being loaded on a carrier. In detail, the virus infection inhibiting compound (polymer 1) is crushed under the operating conditions of a raw material supply rate of 1kg / h and a compressed air pressure of 0.75MPa using a jet mill device (trade name "SJ-500" manufactured by NISSHIN ENGINEERING) to obtain particles of the virus infection inhibiting compound. 5 parts by mass of the virus infection inhibiting compound (polymer 1) shown in Table 2 is mixed with 95 parts by mass of an ultraviolet curing acrylic coating (trade name "AI-N2" manufactured by COAT TECH) to prepare a coating composition (virus infection inhibiting product). The coating composition is used in the same manner as in Example 1 to form a coating film with a thickness of 18μm.

[0211] (Comparative Examples 2 to 9)

[0212] The virus infection inhibition compound shown in the column of "type" in Table 2 is used without being loaded on a carrier. In detail, the virus infection inhibition compound obtained by freeze-drying the virus infection inhibition compound is coarsely crushed under the operating conditions of a rotation speed of 25 rpm and a pressure of 25 t using a roller press device (trade name "150 type" of SEISHIN ENTERPRISE), and then crushed using a jet mill device (trade name "SJ-500" of NISSHIN ENGINEERING) under the operating conditions of a raw material supply speed of 1 kg / h and a compressed air pressure of 0.75 MPa to obtain particles of the virus infection inhibition compound. 5 parts by mass of the virus infection inhibition compound shown in the column of "type" in Table 2 are mixed with 95 parts by mass of an ultraviolet curing acrylic coating (trade name "AI-N2" of COATTECH) to prepare a coating composition. The coating composition is used in the same manner as in Example 1 to form a coating film with a thickness of 18 μm.

[0213] (Comparative Example 10)

[0214] The virus infection inhibiting compound shown in the column of "Type" in Table 2 was used without being supported on a carrier. Specifically, the virus infection inhibiting compound was freeze-dried to obtain a paste of the virus infection inhibiting compound. 5 parts by mass of the virus infection inhibiting compound shown in the column of "Type" in Table 2 was mixed with 95 parts by mass of an ultraviolet curing acrylic coating (COAT TECH Co., Ltd., trade name "AI-N2") to prepare a coating composition. The coating composition was used in the same manner as in Example 1 to form a coating film with a thickness of 18 μm.

[0215] The obtained coating film was tested for antiviral properties, yellowing resistance, and coating properties by the following methods. The results are shown in Tables 1 and 2.

[0216] (Antiviral test)

[0217] A test piece was prepared by cutting out a flat square shape having a side of 5.0 cm from the coating film.

[0218] 1 mL of water was impregnated into a 10 cm square nonwoven fabric (trade name "Kimwipe S-200" manufactured by NIPPON PAPER R CRECIA) and the coating surface of the obtained test piece was wiped with the nonwoven fabric by reciprocating 10 times to prepare a test coating.

[0219] The obtained test coating film was subjected to an antiviral test against influenza virus and feline calicivirus in accordance with ISO 21702. The virus infection titer of the test coating film was calculated by a plaque method for the virus suspension after the reaction.

[0220] A blank coating was prepared in the same manner as above except that the virus infection inhibitor was not contained, and the virus infection titer (common logarithm) (PFU / cm 2 The virus infection titer (common logarithm value) of the blank coating is 6.5 PFU / cm 2 .

[0221] The antiviral activity value was calculated by subtracting the virus infection titer of the test coating from the virus infection titer of the blank coating.

[0222] (Yellowing resistance)

[0223] For the test coating obtained by the same method as the antiviral test, a durability test at 120°C for 1000 hours was implemented. The yellow index of the test coating before and after the test was measured based on AS TM E313-73 using a spectrophotometer ("CM-5" manufactured by Konica Minolta). The yellowing degree (ΔYI) was calculated by subtracting the yellow index before the test from the yellow index after the test. The smaller the value of ΔYI, the less yellowing after the test, which can be judged as a higher yellowing resistance.

[0224] [Applicability]

[0225] The coating composition was evaluated based on JIS K5600-2-5 using a grind gauge to measure the depth of the streaks. The smaller the maximum value of the streak depth, the higher the dispersibility of the virus infection inhibitor in the coating, and the higher the coating properties of the virus infection inhibitor.

[0226] [Masterbatch for synthetic resin molding]

[0227] (Examples 32 to 46, Comparative Example 12)

[0228] Water having a mass of 7 times the total mass of the virus infection inhibiting compound and the carrier was prepared. The virus infection inhibiting compound and the carrier (particles) shown in Table 3 were supplied to water in a given amount and uniformly mixed to prepare a dispersion. The particles used in the carrier had a D50 particle size and specific surface area shown in Table 3.

[0229] Next, the dispersion was powdered using a spray dryer through an atomizer at a rotation speed of 20000 rpm, so that the total amount of the virus infection inhibiting compound was attached (supported) to the surface of the carrier, and then a jet mill device (trade name "SJ-500" manufactured by NISSHIN ENGINEERING) was used to crush the raw material supply speed 1kg / h and the compressed air pressure 0.75MPa under the operating conditions to obtain a carrier on which the virus infection inhibiting compound was already supported (attached) on the surface. The mass ratio of the virus infection inhibiting compound to the carrier (mass of the virus infection inhibiting compound / mass of the carrier) is shown in the "Compound / Carrier" column of Table 3.

[0230] In Examples 32 to 40 and Comparative Example 12, the obtained carrier was used as a virus infection inhibitor. In Examples 41 to 46, an antioxidant was added to the obtained carrier and uniformly mixed to prepare a virus infection inhibitor. The amounts of the virus infection inhibitor compound, carrier, and antioxidant in the virus infection inhibitor were adjusted as shown in Table 3.

[0231] 50 parts by mass of the obtained virus infection inhibitor and 50 parts by mass of polypropylene (trade name "NOVATECPP BC6C" manufactured by JAPAN POLYPROPYLENE CO., LTD.) were uniformly melt-kneaded and mixed to prepare a masterbatch for synthetic resin molding.

[0232] The obtained synthetic resin molding masterbatch and separately prepared polypropylene (PP, trade name "NOVATECPP BC6C" manufactured by JAPAN POLYP ROPYLENE CO., LTD.) were melt-kneaded at 180° C. for 5 minutes at a ratio of 1:9 (mass ratio) to prepare a resin composition.

[0233] The obtained resin composition was press-molded to obtain a sheet-shaped resin molded product having an average thickness of 1 mm as a virus infection inhibiting product.

[0234] The obtained virus infection inhibition product was subjected to an antiviral test by the same test method as in the case of film coating to measure the antiviral activity value. The results are shown in Table 3.

[0235] The yellowing resistance of the obtained virus infection inhibiting product was measured by the same method as in the case of film coating. The results are shown in Table 3.

[0236] [Table 1]

[0237]

[0238] [Table 2]

[0239]

[0240] [Table 3]

[0241]

[0242] Industrial Applicability

[0243] The virus infection inhibitor of the present invention can produce a coating material having excellent coating properties. The virus infection inhibitor of the present invention hardly turns yellow even when left in a high temperature environment and can produce a coating material that forms a coating film having an excellent virus infection inhibitory effect.

[0244] Since the virus infection inhibitor of the present invention has excellent yellowing resistance, it is possible to produce a virus infection inhibitory product having an excellent virus infection inhibitory effect while maintaining the appearance such as the color of the substrate.

[0245] (CROSS-REFERENCE TO RELATED APPLICATIONS)

[0246] This application claims priority based on Japanese Patent Application No. 2022-128501 filed on August 10, 2022 and Japanese Patent Application No. 2022-176594 filed on November 2, 2022, the disclosures of which are incorporated herein by reference in their entirety.

Claims

1. A viral infection inhibitor, comprising: Specific surface area is 1~1000m 2 / g of carrier; and A virus infection inhibitory compound supported on the carrier and containing at least one infection inhibitory functional group selected from carboxyl, sulfonyl, primary amino, secondary amino and tertiary amino groups or a salt thereof, or a virus infection inhibitory compound supported on the carrier and containing a guanidine structure.

2. The viral infection inhibitor according to claim 1, wherein The D50 particle size of the support is 0.1 to 200 μm.

3. The viral infection inhibitor according to claim 1 or 2, wherein The mass ratio of the virus infection inhibiting compound to the carrier (mass of the virus infection inhibiting compound / mass of the carrier) is 0.02-10.

4. The viral infection inhibitor according to claim 1 or 2, wherein The specific surface area of ​​the carrier is 50 to 1000 m 2 / g.

5. The viral infection inhibitor according to claim 1 or 2, wherein The virus infection inhibitory compound is a polymer having a weight average molecular weight of 1,000 or more.

6. The viral infection inhibitor according to claim 1 or 2, wherein The virus infection inhibiting compound is a polymer having a secondary amino group or a guanidine structure.

7. The viral infection inhibitor according to claim 1 or 2, which contains an antioxidant.

8. A resin composition comprising: Synthetic resin, and The viral infection inhibitor according to claim 1 or 2.

9. The resin composition according to claim 8, which is used as a masterbatch for synthetic resin molding.

10. The resin composition according to claim 9, wherein Viral infection inhibitors contain antioxidants.

11. The resin composition according to claim 10, wherein The melting point of the antioxidant is below 200°C.

12. A viral infection inhibition product comprising: Base material, and The viral infection inhibitor according to claim 1 or 2 contained in the substrate.

13. The viral infection inhibiting product according to claim 12, wherein: The base material is paint.

Images